Berfin Gülave studied the master Biomedical Sciences (Neurobiology) at the University of Amsterdam from 2015 to 2017, followed by a second master Drug Innovation at Utrecht University from 2017 to 2019. Since January 2020, she started her PhD project in the H2020 consortium QSPainRelief. The aim of this consortium is to develop a novel in silico modelling platform to evaluate new combinations of existing central nervous system (CNS) drugs with respect to improved analgesia and reduced sedation, cognitive impairment, and abuse liability. The focus of her project will be on predicting the CNS distribution of pain relieving drugs in health and in chronic pain conditions. To this end, data on drug specific properties and species specific characteristics in health and chronic pain will be collected and used in mathematical models for predictions on CNS distribution.

Publications